Clinical trial
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly…
NCT06216158 · University of Heidelberg Medical Center, Other · Recruiting
Key facts
| NCT number | NCT06216158 |
|---|---|
| Title | Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma |
| Official title | A Randomized Phase III Trial Assessing Iberdomide Versus Iberdomide Plus Isatuximab Maintenance Therapy Post Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma |
| Lead sponsor | University of Heidelberg Medical Center, Other |
| Collaborators | KKS Netzwerk Wuerzburg University Hospital Sanofi Industry Bristol-Myers Squibb |
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Iberdomide, Isatuximab, Dexamethasone |
| Enrollment | 411 |
| Start date | Apr 5, 2024 |
| Primary completion | Dec 1, 2028 |
| Completion | Jun 1, 2029 |
| First posted | Jan 22, 2024 |
| Last update posted | Feb 2, 2026 |
| Countries | Austria, Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: